Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms

Lori A. Erickson, Long Jin, Thomas J. Sebo, Christine Lohse, V. Shane Pankratz, Michael L. Kendrick, Jon A. Van Heerden, Geoffrey B. Thompson, Clive S. Grant, Ricardo V. Lloyd

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

We analyzed a series of adrenocortical neoplasms to compare the clinicopathologic features and the expression of insulin-like growth factor-2 (IGF-2) in adrenocortical adenomas and carcinomas. IGF-2 is a growth factor commonly expressed in many tumors including adrenal cortical and medullary neoplasms. Formalin-fixed paraffin-embedded tissues from 64 adrenocortical adenomas and 67 adrenocortical carcinomas were analyzed. The carcinomas were histologically graded from 1 to 4 based on mitotic activity and necrosis. Tumor weight, size, and follow-up information were obtained by chart review. Expression of IGF-2 was detected by immunohistochemistry with the avidin-biotin-peroxidase complex method and a monoclonal antibody against IGF-2. Adrenocortical carcinomas were larger (mean: 13.1 cm, 787 g) than adenomas (mean: 4.2 cm, 52 g) (p < 0.001). In patients with adrenocortical carcinomas, high tumor grade (3 or 4) (p = 0.01) was associated with decreased survival. Expresssion of IGF-2 was higher in adrenocortical carcinomas than in adenomas (p < 0.001). These results show that tumor size and weight along with expression of IGF-2 protein are useful features to assist in distinguishing between adrenocortical adenomas and carcinomas, and that high tumor grade is a predictor of survival in adrenocortical carcinomas. However, single immunohistochemical markers such as IGF-2 or single histopathologic features cannot by themselves separate adrenocortical adenomas from carcinomas, and a combination of clinical, gross, and microscopic features are needed to establish the diagnosis in difficult cases.

Original languageEnglish (US)
Pages (from-to)429-435
Number of pages7
JournalEndocrine Pathology
Volume12
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Adrenocortical Carcinoma
Somatomedins
Adrenocortical Adenoma
Neoplasms
Tumor Burden
Adenoma
Adrenal Gland Neoplasms
Brain Stem Neoplasms
Survival
Avidin
Biotin
Paraffin
Formaldehyde
Peroxidase
Intercellular Signaling Peptides and Proteins
Necrosis
Immunohistochemistry
Monoclonal Antibodies
Carcinoma

Keywords

  • Adrenocortical adenoma
  • Adrenocortical carcinoma
  • Insulin-like growth factor-2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Erickson, L. A., Jin, L., Sebo, T. J., Lohse, C., Pankratz, V. S., Kendrick, M. L., ... Lloyd, R. V. (2001). Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. Endocrine Pathology, 12(4), 429-435. https://doi.org/10.1385/EP:12:4:429

Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. / Erickson, Lori A.; Jin, Long; Sebo, Thomas J.; Lohse, Christine; Pankratz, V. Shane; Kendrick, Michael L.; Van Heerden, Jon A.; Thompson, Geoffrey B.; Grant, Clive S.; Lloyd, Ricardo V.

In: Endocrine Pathology, Vol. 12, No. 4, 2001, p. 429-435.

Research output: Contribution to journalArticle

Erickson, LA, Jin, L, Sebo, TJ, Lohse, C, Pankratz, VS, Kendrick, ML, Van Heerden, JA, Thompson, GB, Grant, CS & Lloyd, RV 2001, 'Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms', Endocrine Pathology, vol. 12, no. 4, pp. 429-435. https://doi.org/10.1385/EP:12:4:429
Erickson, Lori A. ; Jin, Long ; Sebo, Thomas J. ; Lohse, Christine ; Pankratz, V. Shane ; Kendrick, Michael L. ; Van Heerden, Jon A. ; Thompson, Geoffrey B. ; Grant, Clive S. ; Lloyd, Ricardo V. / Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. In: Endocrine Pathology. 2001 ; Vol. 12, No. 4. pp. 429-435.
@article{43eaff24ed8d4aa99361255ba9827493,
title = "Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms",
abstract = "We analyzed a series of adrenocortical neoplasms to compare the clinicopathologic features and the expression of insulin-like growth factor-2 (IGF-2) in adrenocortical adenomas and carcinomas. IGF-2 is a growth factor commonly expressed in many tumors including adrenal cortical and medullary neoplasms. Formalin-fixed paraffin-embedded tissues from 64 adrenocortical adenomas and 67 adrenocortical carcinomas were analyzed. The carcinomas were histologically graded from 1 to 4 based on mitotic activity and necrosis. Tumor weight, size, and follow-up information were obtained by chart review. Expression of IGF-2 was detected by immunohistochemistry with the avidin-biotin-peroxidase complex method and a monoclonal antibody against IGF-2. Adrenocortical carcinomas were larger (mean: 13.1 cm, 787 g) than adenomas (mean: 4.2 cm, 52 g) (p < 0.001). In patients with adrenocortical carcinomas, high tumor grade (3 or 4) (p = 0.01) was associated with decreased survival. Expresssion of IGF-2 was higher in adrenocortical carcinomas than in adenomas (p < 0.001). These results show that tumor size and weight along with expression of IGF-2 protein are useful features to assist in distinguishing between adrenocortical adenomas and carcinomas, and that high tumor grade is a predictor of survival in adrenocortical carcinomas. However, single immunohistochemical markers such as IGF-2 or single histopathologic features cannot by themselves separate adrenocortical adenomas from carcinomas, and a combination of clinical, gross, and microscopic features are needed to establish the diagnosis in difficult cases.",
keywords = "Adrenocortical adenoma, Adrenocortical carcinoma, Insulin-like growth factor-2",
author = "Erickson, {Lori A.} and Long Jin and Sebo, {Thomas J.} and Christine Lohse and Pankratz, {V. Shane} and Kendrick, {Michael L.} and {Van Heerden}, {Jon A.} and Thompson, {Geoffrey B.} and Grant, {Clive S.} and Lloyd, {Ricardo V.}",
year = "2001",
doi = "10.1385/EP:12:4:429",
language = "English (US)",
volume = "12",
pages = "429--435",
journal = "Endocrine Pathology",
issn = "1046-3976",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms

AU - Erickson, Lori A.

AU - Jin, Long

AU - Sebo, Thomas J.

AU - Lohse, Christine

AU - Pankratz, V. Shane

AU - Kendrick, Michael L.

AU - Van Heerden, Jon A.

AU - Thompson, Geoffrey B.

AU - Grant, Clive S.

AU - Lloyd, Ricardo V.

PY - 2001

Y1 - 2001

N2 - We analyzed a series of adrenocortical neoplasms to compare the clinicopathologic features and the expression of insulin-like growth factor-2 (IGF-2) in adrenocortical adenomas and carcinomas. IGF-2 is a growth factor commonly expressed in many tumors including adrenal cortical and medullary neoplasms. Formalin-fixed paraffin-embedded tissues from 64 adrenocortical adenomas and 67 adrenocortical carcinomas were analyzed. The carcinomas were histologically graded from 1 to 4 based on mitotic activity and necrosis. Tumor weight, size, and follow-up information were obtained by chart review. Expression of IGF-2 was detected by immunohistochemistry with the avidin-biotin-peroxidase complex method and a monoclonal antibody against IGF-2. Adrenocortical carcinomas were larger (mean: 13.1 cm, 787 g) than adenomas (mean: 4.2 cm, 52 g) (p < 0.001). In patients with adrenocortical carcinomas, high tumor grade (3 or 4) (p = 0.01) was associated with decreased survival. Expresssion of IGF-2 was higher in adrenocortical carcinomas than in adenomas (p < 0.001). These results show that tumor size and weight along with expression of IGF-2 protein are useful features to assist in distinguishing between adrenocortical adenomas and carcinomas, and that high tumor grade is a predictor of survival in adrenocortical carcinomas. However, single immunohistochemical markers such as IGF-2 or single histopathologic features cannot by themselves separate adrenocortical adenomas from carcinomas, and a combination of clinical, gross, and microscopic features are needed to establish the diagnosis in difficult cases.

AB - We analyzed a series of adrenocortical neoplasms to compare the clinicopathologic features and the expression of insulin-like growth factor-2 (IGF-2) in adrenocortical adenomas and carcinomas. IGF-2 is a growth factor commonly expressed in many tumors including adrenal cortical and medullary neoplasms. Formalin-fixed paraffin-embedded tissues from 64 adrenocortical adenomas and 67 adrenocortical carcinomas were analyzed. The carcinomas were histologically graded from 1 to 4 based on mitotic activity and necrosis. Tumor weight, size, and follow-up information were obtained by chart review. Expression of IGF-2 was detected by immunohistochemistry with the avidin-biotin-peroxidase complex method and a monoclonal antibody against IGF-2. Adrenocortical carcinomas were larger (mean: 13.1 cm, 787 g) than adenomas (mean: 4.2 cm, 52 g) (p < 0.001). In patients with adrenocortical carcinomas, high tumor grade (3 or 4) (p = 0.01) was associated with decreased survival. Expresssion of IGF-2 was higher in adrenocortical carcinomas than in adenomas (p < 0.001). These results show that tumor size and weight along with expression of IGF-2 protein are useful features to assist in distinguishing between adrenocortical adenomas and carcinomas, and that high tumor grade is a predictor of survival in adrenocortical carcinomas. However, single immunohistochemical markers such as IGF-2 or single histopathologic features cannot by themselves separate adrenocortical adenomas from carcinomas, and a combination of clinical, gross, and microscopic features are needed to establish the diagnosis in difficult cases.

KW - Adrenocortical adenoma

KW - Adrenocortical carcinoma

KW - Insulin-like growth factor-2

UR - http://www.scopus.com/inward/record.url?scp=18344376533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344376533&partnerID=8YFLogxK

U2 - 10.1385/EP:12:4:429

DO - 10.1385/EP:12:4:429

M3 - Article

C2 - 11949624

AN - SCOPUS:18344376533

VL - 12

SP - 429

EP - 435

JO - Endocrine Pathology

JF - Endocrine Pathology

SN - 1046-3976

IS - 4

ER -